ATE375169T1 - Modifizierte peptide enthaltende pharmazeutische präparationen - Google Patents

Modifizierte peptide enthaltende pharmazeutische präparationen

Info

Publication number
ATE375169T1
ATE375169T1 AT01945007T AT01945007T ATE375169T1 AT E375169 T1 ATE375169 T1 AT E375169T1 AT 01945007 T AT01945007 T AT 01945007T AT 01945007 T AT01945007 T AT 01945007T AT E375169 T1 ATE375169 T1 AT E375169T1
Authority
AT
Austria
Prior art keywords
peptidel
amino acid
pharmaceutical preparations
preparations containing
containing modified
Prior art date
Application number
AT01945007T
Other languages
English (en)
Inventor
Frank Mattner
Wolfgang Zauner
Walter Schmidt
Michael Buschle
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Application granted granted Critical
Publication of ATE375169T1 publication Critical patent/ATE375169T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01945007T 2000-04-14 2001-04-17 Modifizierte peptide enthaltende pharmazeutische präparationen ATE375169T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT6572000 2000-04-14
PCT/EP2001/004313 WO2001078767A2 (en) 2000-04-14 2001-04-17 Pharmaceutical preparations comprising modified peptides

Publications (1)

Publication Number Publication Date
ATE375169T1 true ATE375169T1 (de) 2007-10-15

Family

ID=3678333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01945007T ATE375169T1 (de) 2000-04-14 2001-04-17 Modifizierte peptide enthaltende pharmazeutische präparationen

Country Status (7)

Country Link
US (1) US20030095979A1 (de)
EP (1) EP1272215B1 (de)
JP (1) JP2003531128A (de)
AT (1) ATE375169T1 (de)
AU (1) AU2001267349A1 (de)
DE (1) DE60130877T2 (de)
WO (1) WO2001078767A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AU2002358616A1 (en) * 2001-12-07 2003-06-17 Intercell Ag Immunostimulatory oligodeoxynucleotides
WO2004011650A2 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP2287315A1 (de) 2003-03-04 2011-02-23 Intercell AG Streptococcus-pyogenes-Antigene
EP1608402B1 (de) 2003-03-24 2010-10-20 Intercell AG Verbesserte impfstoffe
JP2007523609A (ja) 2003-03-31 2007-08-23 インターツェル・アクチェンゲゼルシャフト 表皮ブドウ球菌抗原
EP2311988A1 (de) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae-Antigene
EP2289907A3 (de) 2003-05-07 2011-08-31 Intercell AG Streptococcus agalactiae-Antigene I + II
US20080175856A1 (en) 2003-05-30 2008-07-24 Intercell Ag Enterococcus Antigens
JP4734241B2 (ja) 2003-07-11 2011-07-27 インターツェル・アクチェンゲゼルシャフト Ｈｃｖワクチン
DE602005015605D1 (de) * 2004-10-29 2009-09-03 Intercell Ag Hcv impfstoff für chronische hcv patienten
JP2008519839A (ja) * 2004-11-09 2008-06-12 セルテック バイオサイエンス エルエルシー 癌細胞におけるアポトーシスの増加のための組成物および方法
EP2292644A3 (de) 2006-07-07 2011-05-25 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
JP2010503384A (ja) 2006-09-15 2010-02-04 インターセル アーゲー ボレリア（Ｂｏｒｒｅｌｉａ）抗原
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
CA2675379A1 (en) 2007-01-12 2008-07-17 Intercell Ag Protective proteins of s. agalactiae, combinations thereof and methods of using the same
CN102015754A (zh) 2007-05-02 2011-04-13 英特塞尔股份公司 克雷伯菌（Klebsiella）抗原
CN101883782A (zh) 2007-06-18 2010-11-10 英特塞尔股份公司 衣原体抗原
AU2009226949A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US20130243779A1 (en) 2009-02-05 2013-09-19 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (de) 2009-02-13 2012-01-18 Intercell AG Nicht typisierbare haemophilus influenza-antigene
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
EP3415160B1 (de) 2014-03-04 2021-08-18 Klinikum der Universität München Aus enterococcus abgeleitete polypeptide und deren verwendung zur impfung und erstellung von therapeutischen antikörpern
EP3363459A1 (de) 2017-02-17 2018-08-22 Alexander Klimka Polypeptid-epitope von s. aureus und entsprechende monoklonale antikörper zur behandlung von infektionen und immundiagnose

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
WO1996037107A1 (en) * 1995-05-23 1996-11-28 The Scripps Research Institute Antigen-specific activation of unprimed cd8+ t cells
DE69624815T2 (de) * 1995-05-24 2003-07-10 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
IL123218A0 (en) * 1995-08-18 1998-09-24 Sloan Kettering Inst Cancer Heat shock protein-based vaccines and immunotherapies

Also Published As

Publication number Publication date
JP2003531128A (ja) 2003-10-21
DE60130877D1 (de) 2007-11-22
WO2001078767A2 (en) 2001-10-25
WO2001078767A3 (en) 2002-02-28
AU2001267349A1 (en) 2001-10-30
EP1272215B1 (de) 2007-10-10
DE60130877T2 (de) 2008-07-17
US20030095979A1 (en) 2003-05-22
EP1272215A2 (de) 2003-01-08

Similar Documents

Publication Publication Date Title
ATE375169T1 (de) Modifizierte peptide enthaltende pharmazeutische präparationen
AU764589B2 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
IL92853A0 (en) Human insulin analogues,their preparation and pharmaceutical compositions containing them
AU633913B2 (en) Novel tnf-inhibit proteins and their preparation
KR880009045A (ko) 혈액 응고 방지성 펩티드
BG102714A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
EP1884247A3 (de) Gastrinzusammensetzungen und -formulierungen sowie Verfahren zu deren Herstellung und Verwendung
AU2003264514A1 (en) Wt1 substitution peptides
PH12012502372A1 (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
Shinkai et al. Amino acid sequence of cytochrome c 3 from Desulfovibrio vulgaris, Miyazaki
HUP0105094A2 (hu) IGF-I- és IGF-II-gátló növekedési hormont leadó hormon antagonista analógjai és alkalmazásuk
ATE392428T1 (de) Arzneimittel enthaltend analgetische peptide
KR910007960A (ko) 항응고성 펩티드
NO942360L (no) Vaksine og polypeptider som er nyttige for denne
CA2423004A1 (en) Peptide inhibitors of hiv entry
Corran et al. The tryptic peptides of rabbit muscle triose phosphate isomerase
CA2164712A1 (en) Trifunctional antithrombin and antiplatelet peptides
CA2375224A1 (en) Human antithrombin variants
ATE305478T1 (de) Topoisomerase-ii inhibitoren
Volkova et al. Synthetic fragments of the NS1 protein of the tick-borne encephalitis virus exhibiting a protective effect
RU94036770A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения домена, фармацевтическая композиция, применение домена
Abiko et al. Functional roles of Phe12 of deacetyl‐thymosin β4 in the impaired blastogenic response of uraemic T‐lymphocytes
MY125216A (en) Peptide compositions and formulations and use of same.
MY106188A (en) Biologically active molecules.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272215

Country of ref document: EP

REN Ceased due to non-payment of the annual fee